# Efficacy and Safety of Xueshuanxinmaining Tablet for the Treatment of Stable Angina Pectoris

Study · id `cardio:ct-nct04270279` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04270279](<https://clinicaltrials.gov/study/NCT04270279>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04270279

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT04270279. Randomized; quadruple masking; primary purpose treatment. Start 2020-12 (anticipated); primary completion 2021-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT04270279, source copy `cardio:ctgov-nct04270279-2020-11-13`, retrieved 2026-10-31)
- Planned start: 2020-12 (anticipated) (ClinicalTrials.gov record NCT04270279, source copy `cardio:ctgov-nct04270279-2020-11-13`, retrieved 2026-10-31)
- Primary completion: 2021-08 (anticipated) (ClinicalTrials.gov record NCT04270279, source copy `cardio:ctgov-nct04270279-2020-11-13`, retrieved 2026-10-31)
- Completion: 2021-10 (anticipated) (ClinicalTrials.gov record NCT04270279, source copy `cardio:ctgov-nct04270279-2020-11-13`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04270279-2020-11-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of Xueshuanxinmaining Tablet for the Treatment of Stable Angina Pectoris
- Condition: Coronary Heart Disease
- Condition: Stable Angina
- Intervention (Drug): Xueshuanxinmaining tablet
- Intervention (Drug): Xueshuanxinmaining placebo
- Intervention (Drug): Nitroglycerin tablets
- Lead sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stable angina (`cardio:stable-angina`)
- Registry lists this organization as the lead sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences (`cardio:org-guang-anmen-hospital-of-china-academy-of-chinese-medical-0e53a2`)

## Provenance

Content hash: 6417f33f875277dc25b7ae94a46661c0a49eb15f0ed36aa776d7ffa059cce81c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
